
--- Page 1 ---
1cs-0-3 Crcnoma, infittnatrg ductl Nos 85o/3 Srfe: busst, nos C50.9 s1sh h Diagnosis: A: Lymph node, right axillary sentinel #1, removal - No metastatic carcinoma identified in one lymph node (0/1) B: Lymph node, right axillary sentinel #2, removal - Isolated tumor cell cluster (ITC) identified (on H and E) in one lymph node, 0.12 mm in greatest dimension, negative for extracapsular extension (see comment) C: Lymph node, left axillary sentinel #1, removal - No metastatic carcinoma identified in one lymph node (0/1) D: Lymph node, left axillary sentinel #2, removal - No metastatic carcinoma identified in one lymph node (0/1) E: Breast, right, total mastectomy Tumor Histologic Type: invasive ductal carcinoma Nottingham Combined Histologic Grade: 3 (9 of 9) UUID:71CEC5F6-16E5-46E1-A918-B5E0F6998231 Tubule formation score: 3 TCGA-AQ-A043-01A-PR Nuclear pleomorphism score: 3 Redacted Mitotic Count Score: 3 Focality of tumor: unifocal Tumor size (greatest dimension): 2.7 cm (by gross examination) Lymphovascular invasion: not identified In Situ component: present In Situ component type/architecture pattern: ductal carcinoma in situ (DCIS);  solid, comedo, micropapillary and cribriform patterns In Situ component nuclear grade: 3 In Situ component necrosis: present In Situ component extent/size: DCIS comprises approximately 50% of the tumor and is present admixed with and adjacent to invasive carcinoma Margin Status: Invasive component: widely negative

--- Page 2 ---
In Situ component: widely negative Microcalcifications: present associated with in situ and invasive carcinoma. Hormone receptor studies: results will be issued in an addendum report Other findings: - Biopsy site changes. - Proliferative fibrocystic change including sclerosing adenosis. - Duct ectasia AJCC PATHOLOGIC TNM STAGE: pT2 pN0(i+) pMx Note: The pathologic stage assessment is based on information available at the time of this report, and is subject to change pending clinical review and additional information. F: Breast, left, total mastectomy - Lobular carcinoma in situ - Proliferative fibrocystic change - Duct ectasia - No invasive carcinoma identified Comment: The frozen sections of the right axillary sentinel lymph node # 2 (specimen B). are reviewed and are negative for tumor cells. The isolated tumor cells are only identified on the permanent section levels. Intraoperative Consult Diagnosis: FSA1: Right axillary sentinel lymph node #1, biopsy - No tumor seen (0/1) FSB1: Right axillary sentinel lymph node #2, biopsy. - No tumor seen (0/1) FSC1: Lymph node, left axillary sentinel lymph node #1, biopsy - Negative for metastatic carcinoma in one lymph node (0/1). FSD1: Left axillary sentinel node #2, biopsy. - Negative for metastatic carcinoma in one lymph node (0/1) Gross Description: Received are six appropriately labeled containers. Specimens A-D are received. fresh for frozen section.. Container A is additionally labeled "right axillary sentinel lymph node #1." It.

--- Page 3 ---
holds a 1.5 x 1.0 x 1.0 cm lymph node candidate which is serially sectioned and entirely frozen as FSA1 Container B is additionally labeled "right axillary sentinel lymph node #2." It holds a 1.5 x 1.0 x 1.0 cm yellow/tan lymph node candidate which is serially sectioned and entirely submitted in block FSB1 Container C is additionally labeled "left axillary sentinel lymph node #1." It holds a 2 x 1 x 1 cm aggregate of yellow/tan fibrofatty tissue containing one. lymph node candidate which is serially sectioned and frozen as FsC1. A small amount of fat remains in formalin. Container D is additionally labeled "left axillary sentinel lymph node #2." It holds a 1 x 1 x 1 cm fragment of yellow/tan fibrofatty tissue which is serially sectioned and entirely frozen as FSD1 Container E: Specimen fixation: formalin Time in fixative: 9 hours. Type of mastectomy: total Size of specimen: 25 cm medial to lateral, 20.5 cm superior to inferior, 6.0 cm anterior to posterior; weighing 890 grams Orientation of specimen: There is a long suture lateral, and a short suture. superior. The specimen is inked as follows: superior/blue, inferior/red, deep/black. The specimen is sectioned from medial towards lateral.. Skin ellipse dimensions: 18 x 10 cm Nipple/areola: 1.0 cm/3.0 cm Axillary tail: not present. Biopsy site: not identified Residual tumor: present Location of tumor: upper outer quadrant; The tumor is a centrally necrotic, ill-defined mass which is 2.7 x 2.5 x 2.3 cm. Distance of mass/biopsy site from surgical margin: The tumor is located 1.3 cm

--- Page 4 ---
from the black inked posterior margin, 2 cm from. the blue inked superior soft tissue margin, 8 cm from the red inked inferior soft tissue margin, 3 cm subjacent to the skin, 5. cm from the lateral margin and remote from the medial margin. Gross involvement of skin or fascia/muscle by tumor: absent Description of remainder of breast: composed primarily of fat intermixed with yellow/tan, centrally dense fibroconnective tissue with multiple cysts measuring up to 0.8 cm in greatest dimension Other remarkable features: The tumor is surrounded by dark blue dye staining. Tissue submitted for special investigations: tumor and normal are given to Tissue Procurement Digital photograph taken: none Block Summary: (Inking: superior-blue, inferior-red, deep-black). E1 - nipple, serially sectioned E2 - areola, en face E3 - central tumor E4 - tumor and black inked deep margin. E5 - closest blue inked superior margin E6-E7 - sections of tumor in relationship to adjacent breast parenchyma E8 - upper inner quadrant E9 - lower inner quadrant. E10 - upper outer quadrant E11 - lower outer quadrant Container F: Specimen fixation: formalin Time in fixative: 8.5 hours. Type of mastectomy: total Size of specimen: 22 cm medial to lateral, 25 cm superior to inferior, 5 cm  anterior to posterior; 990 grams Orientation of specimen: Long suture-lateral, short suture-superior Inking: superior-green, inferior-red, deep-black; The specimen is sectioned from medial towards lateral.

--- Page 5 ---
Skin ellipse dimensions: 17.5 x 9.0 cm Nipple/areola: 1.1 cm/3.5 cm Axillary tail: not present Biopsy site: not identified Residual tumor: not present Description of remainder of breast: composed primarily of fat intermixed with. centrally dense white/tan, slightly nodular fibrofatty tissue with multiple cysts measuring up to 1.3 cm in greatest dimension Other remarkable features: There is focal blue dye staining in the central to lower inner quadrant of the breast Tissue submitted for special investigations: normal is given to Tissue Procurement Digital photograph taken: none Block Summary: (Inking: superior-green, inferior-red, deep-black) F1 - nipple, serially sectioned F2 - areola, en face. F3-F4 - upper inner quadrant F5-F6 - lower inner quadrant F7-F8 - upper outer quadrant F9-F10 - lower outer quadrant F11-F12 - central/subareolar Procedures/Addenda: Addendum Addendum The following addendum is issued to report the results of estrogen receptor, progesterone receptor, and HER2/neu immunohistochemical studies. Results: Estrogen receptor . clone SP1): Interpretation: NEGATIVE

--- Page 6 ---
Computer-assisted quantitative score: 0% Progesterone receptor ( clone 1E2): Interpretation: NEGATIVE Computer-assisted quantitative score: 0% HER2/neu ! clone 4B5, FDA-approved): Interpretation: NEGATIVE Computer-assisted quantitative score: 0 Site: right breast Performed on block: E3 Fixation: 10% neutral buffered formalin. Fixation time: 6-48 hours. Reference range: Estrogen receptor and progesterone receptor: <1%=NEGATIVE, 1-10% WEAK POSITIVE, >10% POSITIVE HER2/neu: 0,1=NEGATIVE FOR OVEREXPRESSION, 2=INDETERMINATE 3=POSITIVE FOR OVEREXPRESSION Comment: The quantitative scores reported above were obtained using the FDA-approved The control slides for this case show. appropriate staining. Some of the immunohistochemical reagents used in this case may be classified as analyte specific reagents (ASR) or research use only (RUO) reagents. These were developed and have performance characteristics determined by the These reagents have not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. These tests. are used for clinical purposes. They should not be regarded as investigational. or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity. clinical laboratory testing.